Cancer biomarkers : section A of Disease markers最新文献

{"title":"Combination detection of IgG- and IgA-related autoantibodies for the early diagnosis of gastric cancer.","authors":"Congcong Fu, Tao Wang, Xianzhu Zhou, Jianmin Fang, Yanlin Wang, Yuxin Wang, Xiaomao Yin, Wei Zhu, Hua Dong, Yiqi Du, Shuhong Luo, Ruo-Pan Huang","doi":"10.1177/18758592251363414","DOIUrl":"https://doi.org/10.1177/18758592251363414","url":null,"abstract":"<p><p>BackgroundAutoantibodies against tumor-associated antigens (TAAs) are promising noninvasive cancer biomarkers due to their specificity and stability. Gastric cancer (GC) diagnosis often requires invasive procedures, emphasizing the need for reliable blood-based biomarkers.ObjectiveThis study assessed whether serum IgG and IgA autoantibodies, individually or combined, could serve as noninvasive biomarkers for gastric cancer.Experimental designWe analyzed 27 autoantibodies in serum from 265 healthy controls, 296 GC patients, and 195 gastritis patients using protein microarray. Autoantibody levels and the IgG/IgA ratio were calculated. Diagnostic accuracy was evaluated using receiver operating characteristic (ROC) curves.ResultsWe identified 24 differentially expressed autoantibodies (DEAs) for IgA and 17 for IgG between GC patients and controls. In distinguishing GC from gastritis, 20 DEAs for IgA and 23 for IgG were significant. The IgG/IgA ratio of MIP1 beta had the highest diagnostic performance between atrophic gastritis and GC, while MMP7 was the most effective between chronic gastritis and GC. The gbm model with 14 autoantibodies had the highest Youden's index for GC versus controls, and a 13-autoantibody model performed best for GC versus all gastritis.ConclusionsSpecific panels of autoantibodies could serve as noninvasive diagnostic tools for distinguishing GC from controls and gastritis.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 10","pages":"18758592251363414"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning-driven gene expression profiling for lung cancer stage determination.","authors":"Yinbo Wang, Kai Fu","doi":"10.1177/18758592251367223","DOIUrl":"10.1177/18758592251367223","url":null,"abstract":"<p><p>BackgroundLung cancer remains a leading cause of cancer-related mortality, with accurate staging essential for guiding treatment. Advances in next-generation sequencing (NGS) and machine learning (ML) enable more precise classification, improving on traditional imaging-based methods.ObjectiveThis retrospective study applies XGBoost with cross-validation (CV) to classify early vs. late-stage lung cancer using RNA-Seq data from 993 patients in The Cancer Genome Atlas (TCGA) cohort.MethodsGene selection was conducted using the Wilcoxon rank-sum test on training data, and the XGBoost model was optimized via cross-validation. Model performance was assessed using the Area Under the Curve (AUC), with sensitivity-specificity analysis across classification thresholds.ResultsThe XGBoost model achieved a test AUC of 0.6534, identifying 40 key genes that optimize predictive accuracy while minimizing overfitting. Thresholds of 0.3 and 0.4 were optimal, balancing sensitivity and specificity for clinical application<b>.</b>ConclusionsIntegrating RNA-Seq data with machine learning improves lung cancer staging accuracy. Future research should focus on dataset expansion, model benchmarking, and multi-omics integration to enhance clinical applicability.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 9","pages":"18758592251367223"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of immune cell subsets in liver fibrosis through single-cell RNA sequencing and array.","authors":"Bo Yang, Junjie Yuan, Jingwen Zhao, Xin Chen","doi":"10.1177/18758592251374861","DOIUrl":"10.1177/18758592251374861","url":null,"abstract":"<p><p>BackgroundImmune-inflammatory responses and dysregulation play a key role in liver fibrosis (LF) and cirrhosis progression, but the phenotypic and functional dynamics of immune cell populations remain poorly characterized.MethodsLF-related data from the GEO database were analyzed using ssGSEA to quantify immune cell infiltration and Kaplan-Meier analysis to assess the prognostic value of specific immune cell populations. Single-cell RNA sequencing data were used to establish an immune cell atlas, identify cell types linked to poor prognosis, and validate characteristic genes. Additionally, the functional distinctions and cell-cell interactions were further investigated.ResultsLF patients showed increased infiltration of monocytes, T cells, and NK cells, associated with poor outcomes. Genes linked to poor prognosis were markedly expressed in mononuclear phagocytes, T cells, and innate lymphoid cells (ILCs), which were further classified into 24 distinct subpopulations. Pro-fibrotic scar-associated macrophages and pro-inflammatory ILCs increased, while anti-inflammatory Kupffer cells and protective ILCs decreased. CCR7-expressing T cells and depletion-related genes were elevated in peripheral blood mononuclear cells, with ILCs showing increased expression of S1PR4 and S1PR5. Furthermore, macrophages expressing CD9 and IGFBP7 were identified.ConclusionThis study highlights immune heterogeneity in LF, identifying key cell populations linked to disease progression, offering potential immunotherapy targets.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 9","pages":"18758592251374861"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PDCD2L overexpression represents an unfavorable prognostic marker and its inhibition shows promising therapeutic potential for gastric cancer.","authors":"Ding-Ping Sun, Chun-Chao Chang, Hsuan-Yi Huang, Nai-Weng Kang, You-Cheng Hseu, Yu-Feng Tian, Chia-Lang Fang, Kai-Yuan Lin","doi":"10.1177/18758592251374857","DOIUrl":"https://doi.org/10.1177/18758592251374857","url":null,"abstract":"<p><p>BackgroundGastric cancer is the 4th most common and 3rd deadliest cancer worldwide. Research has shown that PDCD2-like (PDCD2L) is elevated in several tumors.ObjectiveTo explore the relationship between PDCD2L expression and gastric cancer prognosis and its function in gastric cancer.MethodsImmunohistochemical staining and immunoblotting were performed to examine the expression of PDCD2L. The effect of PDCD2L on gastric cancer cells were evaluated by a series of in vitro cellular function experiments and in vivo proliferation experiments.ResultsPDCD2L was found to be overexpressed in gastric cancer tissues compared to non-tumor tissues, and its higher levels were associated with worse prognosis. In vitro experiments showed that reducing PDCD2L expression in gastric cancer cells led to decreased proliferation, migration, and invasion, with a similar effect observed in animal models. Knockdown of PDCD2L also resulted in lower expression of cell cycle- and motility-related proteins, while upregulation of PDCD2L had the opposite effect. Additionally, NGS analysis revealed that PDCD2L knockdown reduced the expression of RFX1, a gene linked to cell proliferation and migration, suggesting that PDCD2L and RFX1 together promote cancer progression.ConclusionPDCD2L could serve as a biomarker for gastric cancer prognosis and a potential therapeutic target.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 9","pages":"18758592251374857"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144985920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the role of PREX2 mutations as a biomarker for immunotherapy response in colorectal cancer.","authors":"Huan Peng, Pengmin Yang, Xintao Wang, Xiaokai Zhao, Jieyi Li, Ziying Gong, Daoyun Zhang, Zhiguo Wang","doi":"10.1177/18758592251380454","DOIUrl":"https://doi.org/10.1177/18758592251380454","url":null,"abstract":"<p><p>IntroductionImmunotherapy benefits gastrointestinal tumor patients. But traditional biomarkers like TMB and MSI can't precisely identify beneficiaries. Phosphatidylinositol - 3,4,5 - triphosphate - dependent Rac exchange factor 2 (PREX2) plays a complex role in tumorigenesis.MethodsIn a retrospective study of 1764 patients (1385 colorectal, 379 gastric), NGS of 639 genes and PD - L1 staining were done.ResultsIn colorectal cancer, PREX2 mutations were associated with increased TMB, MSI, TMB-H, and MSI-H. Mechanistically, this is related to an increased number of tumor pathway mutations, higher PD - L1 expression, increased immune infiltration, and immune - related pathway enrichment. Cetuximab and Bortezomib sensitivity was higher in PREX2 - mutated colorectal cancer. In gastric cancer, there are no established immune associations with PREX2 mutations.ConclusionPREX2 mutations may serve as a novel predictive biomarker for immunotherapy in CRC, potentially enhancing antitumor immunity via microenvironment modulation, but lack predictive value in GC. These findings highlight PREX2's role in refining patient stratification for immune checkpoint inhibitors.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 9","pages":"18758592251380454"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145093172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumour microbiota activities associated with local recurrence in ER + PR + breast cancer.","authors":"Sean Si Qian Ma, Luyi Ye, Fan Zhang, Tiansheng Xu, Zai-Si Ji, Enuo Liu","doi":"10.1177/18758592251381084","DOIUrl":"https://doi.org/10.1177/18758592251381084","url":null,"abstract":"<p><p>PurposeThis study aimed to compare tumour microbiota characteristics as potential recurrence predictors in estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) breast cancer.MethodsFormalin-fixed paraffin-embedded (FFPE) tumour tissues were obtained from 52 patients with ER + PR + breast cancer, and patients were retrospectively followed up for over 7 years. Patients were categorized into three groups: local recurrence (n = 13), distant metastasis (n = 17), and no recurrence (n = 22). Gene expression profiles and microbial activity in tumour tissues were analyzed by microarray and 16S rRNA sequencing, respectively, from the same total RNA extracted from FFPE samples.ResultsCompared to nonrecurrent tumours, the ratio of strict anaerobic bacteria <i>Muribaculaceae</i> to aerobic bacteria <i>Pseudomonas</i> activity was significantly upregulated in tumours with local recurrence, while no significant difference was observed in the distant metastasis group. Furthermore, the <i>Muribaculaceae/Pseudomonas</i> activity ratio showed a significant correlation with the cancer relating genes expression of <i>PLA2G5, MSMO1</i>, and three small nuclear RNAs across all 52 tumours.ConclusionThis study provided the first evidence of distinctive features of tumor-associated microbiota in ER+/PR + breast cancer patients with local recurrence, suggesting their potential as predictive biomarker for local recurrence. However, these findings require further validation in larger cohorts due to the limited sample size.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 9","pages":"18758592251381084"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145153163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A risk model based on signature genes predicts prognosis and associates with tumor immunity, drug sensitivity in breast cancer.","authors":"Yuan Li, Hao Li, Jichuan Quan, Ping Bi, Xuemei Liu, Yanwei Yao, Yanqin Peng, Congrui Wang, Xiaofang Gao, Junfang Duan, Xiaoru Wang, Jian Peng","doi":"10.1177/18758592251357078","DOIUrl":"10.1177/18758592251357078","url":null,"abstract":"<p><p>BackgroundBreast cancer, the leading cause of cancer deaths among women, exhibits high heterogeneity, affecting prognosis. Understanding this heterogeneity and developing prognostic models are crucial for accurate identification of high-risk patients.MethodsAccessing breast cancer gene expression and clinical data from public datasets, we identified differential expression genes in tumor vs. non-tumor tissues using TCGA data. Key DEGs were then selected using LASSO and Cox regression, and a prognostic risk model (BRCA-DEGs-LASSO-Cox) was constructed. Survival analysis estimated model predictability, identifying high-risk patients. Correlation between risk score and signaling pathways, immune status, and drug sensitivity was analyzed. Molecular mechanisms underlying high-risk patients were discussed.ResultsOur analysis identified 1217 downregulated and 689 upregulated DEGs in breast cancer tumor tissues. A BRCA-DEGs-LASSO-Cox model was constructed using four key DEGs, stratifying patients into high/low-risk groups. High-risk patients had worse OS across cohorts and were associated with androgen, estrogen, and PI3 K signaling pathway dysregulation. They also exhibited immune status dysregulation and drug sensitivity disturbances. Molecular mechanism analysis indicated abnormal regulation of cell cycle, mitosis, and immune-related signals in high-risk patients, explaining their poorer prognosis.ConclusionsBRCA-DEGs-LASSO-Cox model effectively identifies high-risk breast cancer patients, revealing key signaling pathways, immune status, drug sensitivity, and molecular mechanisms.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 7","pages":"18758592251357078"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144736589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hsa_circ_0101308 adjusted by N6-methyladenosine (m⁶A) impacts chemo-resistance in cervical cancer via sponging miR-224.","authors":"Li Shang, Ruchun Yan, Heng Wang, Zhuyan Li","doi":"10.1177/18758592251341157","DOIUrl":"https://doi.org/10.1177/18758592251341157","url":null,"abstract":"<p><p>BackgroundConsidering the significance of circRNA-miRNA network underlying cervical cancer (CC) development, this investigation was devised to explore whether and how 6-methyladinosinek (m⁶A)-adjusted hsa_circ_0101308/miR-224 axis participated in altering chemo-resistance in CC.MethodsForty-nine pairs of CC tissues and para-cancerous normal tissues were gathered, and CC cell lines, comprising HeLa, HeLa/DDP, HeLa/ADM and HeLa/TAX cell lines, were pre-prepared. Expressions of circRNAs, miRNAs and mRNAs were determined using quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and m⁶A-modification of hsa_circ_0101308 was verified based on methylated RNA immunoprecipitation sequencing (MeRIP-Seq) assay. Among CC cell lines, their chemo-resistance was evaluated through CCK8 assay, and their viability was assessed via MTT assay.ResultsHsa_circ_0101308 expression markedly dwindled, accompanied by notably elevated expression of miR-224, within CC tissues, when compared with para-cancerous normal tissues (<i>P</i> < 0.05). Hsa_circ_0101308 sponed miR-224 and suppressed its expression in HeLa cell line (<i>P</i> < 0.05), and either under-expressed m⁶A-adjusted hsa_circ_0101308 or over-expressed miR-224 strengthened viability of HeLa, HeLa/DDP, HeLa/ADM and HeLa/TAX cell lines (<i>P</i> < 0.05). Additionally, miR-224 targeted CADM1 and down-regulated its mRNA level (<i>P</i> < 0.05), which influenced p-PI3K/PI3K or p-Akt/Akt ratio (<i>P</i> < 0.05).ConclusionThe network combined by m⁶A-adjusted hsa_circ_0101308 and miR-224 interfered with chemo-resistance in CC via acting upon CADM1 and PI3K/AKT pathway, which was conducive to optimizing CC treatment.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 6","pages":"18758592251341157"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of Concern: \"Long non-coding RNA <i>LINC00641</i> suppresses non-small-cell lung cancer by sponging <i>miR-424-5p</i> to upregulate <i>PLSCR4</i>\".","authors":"","doi":"10.1177/18758592251352767","DOIUrl":"https://doi.org/10.1177/18758592251352767","url":null,"abstract":"","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 6","pages":"18758592251352767"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of serum HMGB1, SAA, and TSGF in patients with colon cancer and the value of prognostic assessment.","authors":"Kaifeng Wang, Junxing Huang","doi":"10.1177/18758592241297848","DOIUrl":"https://doi.org/10.1177/18758592241297848","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the expression of serum high mobility group protein 1 (HMGB1), amyloid A (SAA), and tumor-specific growth factor (TSGF) in patients with colon cancer (CRC) and the value of prognostic assessment. &lt;b&gt;Methods:&lt;/b&gt; Sixty cases of CRC patients admitted to our hospital from January 2018 to December 2020 were selected and set as the CRC group; 60 cases of inflammatory bowel disease (IBD) patients admitted during the same period were set as the IBD group, and 60 cases of those who were admitted to the hospital for health experience during the same period were set as the control group. The serum HMGB1, SAA, and TSGF levels of each group were detected to analyze their expression in CRC patients and their relationship with prognosis, compare the serum HMGB1, SAA, and TSGF levels of each group, and compare the serum HMGB1, SAA, and TSGF levels of patients with CRC with different clinical features. After 8 to 36 months of follow-up, CRC patients were grouped according to their prognosis (good prognosis group and poor prognosis group), and serum HMGB1, SAA, and TSGF levels were compared between the two groups. The predictive value of serum HMGB1, SAA, TSGF and their combined assays on the prognosis of CRC patients was analyzed using the subject's work characteristic curve (ROC). &lt;b&gt;Results:&lt;/b&gt; Serum HMGB1, SAA, and TSGF levels were significantly higher in the CRC group than in the IBD group (&lt;i&gt;P &lt;/i&gt;&lt; 0.05), and serum HMGB1, SAA, and TSGF levels were significantly higher in the IBD group than in the control group (&lt;i&gt;P &lt;/i&gt;&lt; 0.05). Serum HMGB1, SAA, and TSGF levels were significantly higher in the CRC group than in the patients with TNM staging III than in the patients with TNM staging I-II (&lt;i&gt;P &lt;/i&gt;&lt; 0.05). Serum HMGB1, SAA, and TSGF levels were significantly higher in patients with low differentiation than in patients with middle and high differentiation (&lt;i&gt;P &lt;/i&gt;&lt; 0.05), serum HMGB1, SAA, and TSGF levels were significantly higher in patients with low differentiation than in patients with intermediate and high differentiation (&lt;i&gt;P &lt;/i&gt;&lt; 0.05), and serum HMGB1, SAA, and TSGF levels were significantly higher in those who developed lymph node metastasis than in patients with intermediate and high differentiation (&lt;i&gt;P &lt;/i&gt;&lt; 0.05). Serum HMGB1, SAA, and TSGF levels in the poor prognosis group were significantly higher than those of patients in the good prognosis group (&lt;i&gt;P &lt;/i&gt;&lt; 0.05). The ROC curves showed that the area under the curve (AUC) of serum HMGB1, SAA, and TSGF for predicting the prognosis of patients with CRC were 0.790, 0.774, 0.733, respectively, and that the combined assay predicted the prognosis of patients with CRC with an AUC of 0903, which was higher than that of the test alone (&lt;i&gt;Z &lt;/i&gt;= 2.536, 2.420, 2.218, &lt;i&gt;P &lt;/i&gt;= 0.013, 0.020, 0.031). &lt;b&gt;Conclusion:&lt;/b&gt; Serum HMGB1, SAA, and TSGF expression was significantly higher in colon cancer patients than in patients with inflammatory bowel disease an","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 6","pages":"18758592241297848"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}